The outbreak of Ebola virus disease (EVD) in Western Africa that started in November 2013 ([@R1]) is the largest recorded filovirus disease outbreak. As the outbreak continues, public health and emerging infectious disease officials have declared a continuing need for real-time monitoring of Ebola virus (EBOV) evolution ([@R2],[@R3]). As of March 11, 2015, a total of 41% of reported cases had been fatal ([@R4]). By the end of March 2015, the intensity of the outbreak, which throughout its course affected 6 Western Africa countries, appeared to be receding, with near 0 activity in Liberia and no cases in Mali, Nigeria, and Senegal. However, EBOV continues to spread in Guinea and Sierra Leone. The epidemic is still causing more infections per week than have been recorded in previous EVD outbreaks ([@R5]). Therefore, public health officials continue to use media to maintain public awareness, to advocate for diligent handwashing and use of other protective measures, and to avoid complacency that could lead to reemergence ([@R5]). Vigilance is of paramount importance because currently used assays for EVD diagnosis, and many medical countermeasures in development, were designed using EBOV reference genome variants from previous outbreaks ([@R6]--[@R9]). Therefore, monitoring EBOV genomic drift is crucial because genetic changes can affect the efficacy of sequence-based therapeutics and diagnostics.

The size and spread of the current EVD outbreak reinforces the need to build public health infrastructure, including state-of-the-art diagnostic and surveillance capabilities, to implement and maintain effective EVD monitoring, treatment, and prevention platforms. The Liberian Institute for Biomedical Research (LIBR), established in 1975, is located in Charlesville, 50 km southeast of Liberia's capital, Monrovia. As of April 2, 2015, it is one of the few local facilities within Liberia processing clinical samples from persons suspected to have EVD. A consortium comprising US government and nongovernment agencies has been working with the Liberian government to equip LIBR with advanced genomic sequencing capabilities. These capabilities are dedicated primarily to EVD surveillance activities, including genome sequencing of EBOV-positive samples. The new LIBR Genome Center has a Miseq sequencer (Illumina, San Diego, CA, USA) and ancillary supporting capabilities, including electrophoresis for qualification, fluorometry for quantitation, PCR for amplification, and fully functional computational analysis capabilities to perform pathogen discovery and microbial genome characterization. The US Army Medical Research Institute of Infectious Diseases (USAMRIID) Center for Genome Sciences supports LIBR operation and development. Sample preparation procedures under biosafety containment are provided within the same building complex by the Liberian National Reference Laboratories, operated by USAMRIID and the National Institutes of Health Integrated Research Facility Ebola Response Team (Fort Detrick, Frederick, MD, USA). Throughput at the LIBR Genome Center is 10--20 samples (≈10 billion bases of sequence data) per week, with a target turnaround time of 7 days from sample receipt for high-priority samples. To ensure long-term sustainment of surveillance-based sequencing capabilities, local biomedical scientists have been trained and can proficiently perform all daily activities.

Here we demonstrate the utility and capabilities of the LIBR Genome Center. With the immediate goal of continuing the natural history characterization of the EBOV Makona variant (EBOV/Mak \[[@R10]\]) currently circulating in Western Africa and to support ongoing clinical trials to evaluate candidate medical countermeasures, we describe 25 EBOV genome sequences from the first 5 sequencing runs conducted at the LIBR Genome Center. We chose these samples for full-genome characterization from ≈1,700 available samples on the basis of high viral load (cycle threshold \[C~t~\]) value [\<]{.ul}24) and date of collection to ensure up-to-date temporal coverage.

Materials and Methods
=====================

Samples
-------

We chose samples from 25 patients from the larger collection (≈1,700 positive cases) on the basis of diagnostic C~t~ values that indicated a high enough viral load to provide a full genome (C~t~[\<]{.ul}24), beginning with the most recent available at the time of preparation in February 2015. Sampling continued with progressively older samples to describe the lineages most likely to still be circulating at the time. These patients were treated in 7 different Ebola treatment units and had resided in 7 of the 15 counties in Liberia ([Table 1](#T1){ref-type="table"}; [Technical Appendix 1](#SD1){ref-type="local-data"} [Figure 1](#F1){ref-type="fig"}). Plasma or oral swab samples from which viral RNA was recovered and sequenced were tested at LIBR during September 23, 2014--February 14, 2015. Patients' ages were as follows: 1 infant (1 year), 6 children (2--15 years), 8 young adults (18--35 years), and 10 middle-aged adults (42--67 years). The male:female ratio was 2:1. However, among ≈1,700 samples at LIBR from persons with EVD, the ratio was close to 1:1 (48%/52%), and viral load did not differ by patient sex, which demonstrates that our higher ratio is a sampling artifact.

###### Characteristics of Ebola virus samples from selected patients, Liberia, September 2014--February 2015\*

  Sample ID   Patient age, y/sex   County of residence   Test date     Sample type   Average C~t~ value†
  ----------- -------------------- --------------------- ------------- ------------- ---------------------
  LIBR10054   53/M                 Bomi                  2014 Sep 23   Plasma        20.5
  LIBR10053   42/NA                Not Available         2014 Oct 1    NA            22
  LIBR0058    67/M                 Rivercess             2014 Nov 5    NA            22
  LIBR0059    27/M                 Rivercess             2014 Nov 5    NA            22
  LIBR0073    27/M                 Grand Bassa           2014 Nov 6    Plasma        18.5
  LIBR0067    29/NA                Bomi                  2014 Nov 6    Plasma        21
  LIBR0063    3/F                  Montesserrado         2014 Nov 6    Oral swab     17.5
  LIBR0093    47/M                 Montesserrado         2014 Nov 6    Plasma        15.5
  LIBR0092    18/F                 Montesserrado         2014 Nov 8    Plasma        21
  LIBR0090    62/F                 Margibi               2014 Nov 8    Plasma        22
  LIBR0116    4/F                  Grand Bassa           2014 Nov 10   Plasma        19
  LIBR0168    15/M                 Bomi                  2014 Nov 13   Plasma        22.5
  LIBR0176    42/M                 Montesserrado         2014 Nov 14   Oral swab     22.5
  LIBR0173    64/M                 Montesserrado         2014 Nov 14   Oral swab     22
  LIBR0286    9/F                  Grand Cape Mount      2014 Nov 22   Plasma        22
  LIBR0333    35/F                 Grand Cape Mount      2014 Nov 25   Plasma        19.5
  LIBR0423    45/F                 Montesserrado         2014 Dec 3    Plasma        21.5
  LIBR0430    1/M                  Grand Bassa           2014 Dec 3    Oral swab     23.5
  LIBR0503    8/F                  Sinoe                 2014 Dec 10   Plasma        23
  LIBR0505    29/F                 Sinoe                 2014 Dec 10   Plasma        25
  LIBR0605    2/M                  Montesserrado         2014 Dec 20   Oral swab     23
  LIBR0624    53/M                 Montesserrado         2014 Dec 22   Plasma        19.5
  LIBR0993    33/M                 Montesserrado         2015 Jan 20   Plasma        19.5
  LIBR1195    35/M                 Margibi               2015 Feb 2    Oral swab     22.5
  LIBR1413    56 M                 Montesserrado         2015 Feb 14   Plasma        22.5

\*C~t~, cycle threshold; ID, identification; NA, not available. †C~t~ values used as indicator of viral load obtained from 2 diagnostic assays performed on all samples (Kulesh-TM and Kulesh-MGB \[*9*\]).

![A) Median-joining haplotype network constructed from a full-genome alignment of 122 clinical Ebola virus Makona (EBOV/Mak) isolates (list of isolates in [Technical Appendix 3](#SD1){ref-type="local-data"}). Each colored vertex represents a sampled viral haplotype, with the numbered vertices representing the centers of the 3 clusters described in ([@R12]). All sampled isolates from Liberia originated from cluster 2. The size of each vertex is relative to the number of sampled isolates, and the colors indicate country of origin. Hatch marks indicate the number of mutations along each edge. Because of missing data, 2,764 sites (14.6% of total genome) were excluded from the analysis, including 26 sites with variability among isolates (16.7% of all variable sites). B) Root-to-tip distance correlates well with test date and estimates a rate of evolution equal to 9.17 × 10^−4^ substitutions/site/year. This analysis comprises 110 clinical EBOV/Mak isolates collected during March 17, 2014--January 20, 2015 ([Technical Appendix 3](#SD1){ref-type="local-data"}, isolates with dates).](15-0522-F1){#F1}

Sample Processing
-----------------

RNA was converted to cDNA and amplified by using sequence-independent single-primer amplification ([@R11]). Amplified cDNA was quantified with a Qubit 3.0 fluorometer (Life Technologies, Carlsbad, CA, USA) and used as the starting material for the Illumina Nextera XT DNA library preparation kit (Illumina). Sequencing was performed on an Illumina Miseq by using either V2 or V3 reagent kits (Illumina) with a minimum of 2 × 151 cycles per run.

Genome Assembly
---------------

We assembled EBOV genomes by aligning reads to the genome of Ebola virus/H.sapiens-wt/SLE/2014/Makona-G3686.1 (GenBank accession no. KM034562.1) ([@R12]). Amplification primers were removed from the sequencing reads by using Cutadapt version 1.21 ([@R13]), and low-quality reads/bases were filtered by using Prinseq-lite version 0.20.4 (-min_qual_mean 25 -trim_left 20 -min_len 50) ([@R14]). Reads were aligned to the reference genome by using DNAStar Lasergene nGen (DNAStar, Madison, WI, USA), and a new consensus was generated by using a combination of Samtools v0.1.18 ([@R15]) and custom scripts. Only bases with Phred quality score [\>]{.ul}20 were used in consensus calling, and a minimum of 3× read-depth coverage, in support of the consensus, was required to make a call; positions lacking this depth of coverage were treated as missing (i.e., called as "N").

Genetic Analysis
----------------

Consensus sequences generated here were aligned with additional publically available EBOV genomes by using Sequencher version 5.2.3 (Gene Codes, Ann Arbor, MI, USA). SnpEff version 4.1b (build 2015-02-13) was used to annotate all single-nucleotide polymorphisms (SNPs) by using the genome of Ebola virus/H.sapiens-wt/GIN/2014/Makona-C15 (GenBank accession no. KJ660346.2) as a reference ([@R16]). All 25 genomes from Liberia were used to identify variable sites. For the rest of the genetic analysis, we used only the 14 sequences with \>90% genome coverage. A median-joining haplotype network was constructed in PopART version 1.7.2 (<http://popart.otago.ac.nz>). Path-O-Gen version 1.4 ([@R17]) was used to calculate the root-to-tip distances by using a maximum-likelihood phylogeny (PhyML version 3.0 ([@R18]); general time reversible model) with rooting based on the EBOV phylogeny published by Gire et al. ([@R12]). BEAST version 1.8.2 ([@R17]) was used to estimate the mutation rate and the time to the most recent common ancestor for several evolutionary lineages that included Liberia EBOV isolates. For analysis, we divided the alignment into 3 partitions (i.e., first + second codon sites, third codon site, and noncoding sites). The substitution process was modeled independently for each by using the Hasegawa, Kishino, and Yano model with 4 gamma categories. An exponential growth coalescent model was used with a strict clock. The XML input file is available on request from the authors.

Results
=======

From the first 5 sequencing runs, we obtained 25 EBOV genomes with \>50% coverage; 6 of these were coding complete ([Table 2](#T2){ref-type="table"}) ([@R19]). These genomes contained 97 new sequence variants: 47 synonymous, 23 nonsynonymous, 1 nonsense, and 26 noncoding mutations ([Technical Appendix 2](#SD1){ref-type="local-data"}). Multiple distinct evolutionary lineages were detected, but all were consistent with a single introduction of a cluster 2--type ([@R12]) virus into Liberia followed by within-country diversification ([Figure 1](#F1){ref-type="fig"}, panel A). Because 19 of the 25 genomes had calls at all 5 positions that discriminate clusters 1, 2, and 3, we have high confidence in cluster attribution.

###### Next-generation sequencing of 25 Ebola virus isolates derived from selected patients sampled, Liberia, September 2014--February 2015

  Sample ID   Coverage, %\*   No. reads   Finishing category†   GenBank accession no.
  ----------- --------------- ----------- --------------------- -----------------------
  LIBR0093    99.4            169,000     Coding complete       KR006947
  LIBR0116    97.9            710,168     Coding complete       KR006948
  LIBR10054   98              2,150,725   Coding complete       KR006964
  LIBR0073    98.5            3,351,831   Coding complete       KR006944
  LIBR0503    98.9            3,193,168   Coding complete       KR006956
  LIBR0286    98.3            1,731,953   Coding complete       KR006952
  LIBR0993    96.5            750,000     Standard draft        KR006960
  LIBR0423    97.1            2,676,454   Standard draft        KR006954
  LIBR0333    97.1            1,775,653   Standard draft        KR006953
  LIBR10053   98              1,691,652   Standard draft        KR006963
  LIBR0067    97              2,403,590   Standard draft        KR006943
  LIBR0092    93.9            2,758,142   Standard draft        KR006946
  LIBR0090    93.1            1,422,271   Standard draft        KR006945
  LIBR1413    88.2            2,500,000   Standard draft        KR006962
  LIBR0058    91.4            1,632,978   Standard draft        KR006940
  LIBR0176    89.4            1,907,863   Standard draft        KR006951
  LIBR0168    89.2            1,221,075   Standard draft        KR006949
  LIBR0505    83.8            741,165     Standard draft        KR006957
  LIBR1195    73.1            2,200,773   Standard draft        KR006961
  LIBR0624    68              1,550,511   Standard draft        KR006959
  LIBR0063    69              2,883,384   Standard draft        KR006942
  LIBR0173    72.3            1,456,490   Standard draft        KR006950
  LIBR0059    59.1            851,606     Standard draft        KR006941
  LIBR0605    64.7            1,587,732   Standard draft        KR006958
  LIBR0430    56.2            3,139,009   Standard draft        KR006955

\*Percentage of genome bases (of 18,959 total bases) called in the consensus sequences (requires [\>]{.ul}3× coverage with base quality [\>]{.ul}20). †Categories are defined in ([@R19]).

Molecular dating places the common ancestor to all of the sampled isolates from Liberia during May 2--July 9, 2014 (95% highest posterior density \[HPD\] interval), which corresponds with the early days of the outbreak in Monrovia ([@R3]). However, we cannot rule out ongoing EBOV exchange among EVD-infected countries. In fact, shared ancestry among 3 isolates from Liberia and the 4 available sequences from Mali suggests some level of international movement. We estimated dates associated with 2 nodes along the shared Liberia/Mali EBOV lineage (labeled \* and \*\* in [Figure 1](#F1){ref-type="fig"}, panel A**)**; these estimates ranged from July 6 through September 15, 2014, and from July 26 through September 27, 2014, respectively (95% HPD). Overall, collection dates correlated well with root-to-tip distances within the Western Africa EVD outbreak ([Figure 1](#F1){ref-type="fig"}, panel B). Linear regression analysis (using the lm function in R version 3.1.1; <http://www.r-project.org/>) estimated an overall rate of change of 9.17 × 10^−4^ substitutions/site/year (± 5.23 × 10^−5^). Bayesian analysis estimated a similar rate of change of 9.44--15.67 × 10^−4^ substitutions/site/year (95% HPD).

We reviewed all publicly available genomic information for EBOV/Mak (122 genome sequences \[[@R1],[@R12]\]) to evaluate the effect of genomic drift on biomedical countermeasures (drugs and diagnostic assays). We assessed the potential impact of intra-outbreak genetic divergence on 13 drugs and 2 diagnostic assays (known to be used in Liberia) with the same approach previously used ([@R6]). Two sequence-binding treatment modalities are available for postexposure treatment of EVD: small interfering RNAs (siRNAs) ([@R20]) and phosphorodiamidate morpholino oligomers ([@R21]) targeting *L*, *VP24*, and/or *VP35* gene transcripts, and passive immunotherapy based on antibodies or antibody cocktails targeting EBOV glycoprotein ([@R22]--[@R26]). These treatments inhibit viral replication by targeting viral transcripts for degradation (siRNA) or by blocking translation (phosphorodiamidate morpholino oligomers), or they acutely neutralize the virus to enable the host to mount an effective immune response (passive immunotherapy). These countermeasures were originally designed specifically against sequences obtained during previous outbreaks ([@R20],[@R27]) or were generated against their glycoproteins (e.g., the monoclonal antibodies \[mAbs\] were obtained after immunization with Ebola virus/H.sapiens-tc/COD/1995/Kikwit-9510621 \[EBOV/Kik-9510621\] \[[@R28]\]).

Since the Western Africa outbreak began, at least 33 viral mutations have occurred that could affect countermeasures. We previously reported 27 of these mutations ([@R6]). Twenty-six (79%) mutations induced nonsynonymous changes to epitopes recognized by mAbs included in passive immunotherapy cocktails. Another 5 (15%) were located in published binding regions of siRNA-based therapeutic drugs. Tekmira has adjusted its siRNAs to account for 4 of these 5 changes since its initial publication ([@R29]; E.P. Thi et al., unpub. data). The final 2 mutations were located in the published binding region of primers or probes for quantitative PCR diagnostic tests that have been used during outbreak control activities in Liberia: 1 change each in the binding sites of the Kulesh-TM assay and the Kulesh-MGB assay ([@R9]). Nevertheless, reassessment of the assays at USAMRIID has suggested that the changes will be tolerated without loss in sensitivity (data not shown). Changes in all EBOV/Mak sequences are considered "interoutbreak" (n = 23); changes observed only in some sequences from Western Africa are considered "intraoutbreak" sites (n = 10, EBOV-WA \<100%). We also examined the binding sites of an additional 18 publicly available EBOV quantitative PCRs, which might (or might not) also be used in Western Africa ([Technical Appendix 1](#SD1){ref-type="local-data"} [Figure 2](#F2){ref-type="fig"}, [Technical Appendix 1](#SD1){ref-type="local-data"} Table). We observed 25 changes, of which 6 were reported previously ([@R12]). Each SNP has the potential to affect the efficacy of available therapeutic drugs (original and updated versions) or diagnostic assays ([Table 3](#T3){ref-type="table"}; [Figure 2](#F2){ref-type="fig"}; [Technical Appendix 1](#SD1){ref-type="local-data"} [Figure 2](#F2){ref-type="fig"}, [Technical Appendix 1](#SD1){ref-type="local-data"} Table; nucleotide positions are reported relative to EBOV/Kik-9510621, for consistency \[[@R6]\]).

![Mutation analysis of candidate therapeutic drug and diagnostic binding sites used in outbreak of Ebola virus (EBOV) disease, Western Africa. A single-nucleotide polymorphism (SNP) table is combined with a heat map based on 2 categories: 1) mutations tolerated by the therapeutic drug or diagnostic target (highlighted in green); 2) mutations within the binding region of a therapeutic drug or diagnostic assay that have not yet been tested (highlighted in yellow/orange) ([@R20]*--*[@R24]*,*[@R27]*,*[@R30]*,*[@R31]). Changes previously described are highlighted in yellow; changes that appeared during circulation in Liberia are highlighted in orange. The reference nucleotide positions reported here are in relation to EBOV/Kik-9510621 (GenBank accession no. AY354458), which is one of the primary isolates used as reference for developing these therapeutic drugs and diagnostic assays. A summary of the changes to the probes is available in [Technical Appendix 1](#SD1){ref-type="local-data"} Table. PMO, phosphorodiaminate morpholino oligomer, mAB, monoclonal antibody; siRNA, small interfering RNA; Ref pos, reference positive; VP, viral protein.](15-0522-F2){#F2}

###### Mutation analysis of candidate therapeutic drug and diagnostic binding sites for EBOV\*

  Reference position   Type   Reference base   Called base   EBOV-WA, %   EBOV-LIB, %   Codon                 Feature name
  -------------------- ------ ---------------- ------------- ------------ ------------- --------------------- --------------
  850                  SNP    A                G             100          100           G:GGA @ 127 → G:GGg   NP
  852                  SNP    A                G             100          100           K:AAA @ 128 → R:AgA   NP
  895                  SNP    A                G             100          100           T:ACA @ 142 → T:ACg   NP
  907                  SNP    T                C             1            0             N:AAT @ 146 → N:AAc   NP
  919                  SNP    T                C             100          100           F:TTT @ 150 → F:TTc   NP
  1288                 SNP    A                T             1            0             V:GTA @ 273 → V:GTt   NP
  1495                 SNP    A                G             100          100           Q:CAA @ 342 → Q:CAg   NP
  1498                 SNP    C                T             1            4             L:CTC @ 343 → L:CTt   NP
  1507                 SNP    T                A             100          100           A:GCT @ 346 → A:GCa   NP
  1552                 SNP    C                T             100          100           R:CGC @ 361 → R:CGt   NP
  1862                 SNP    A                G             100          100           S:AGC @ 465 → G:gGC   NP
  6359                 SNP    T                C             100          100           N:AAT @ 107 → N:AAc   GP
  6909                 SNP    T                A             1            0             W:TGG @ 291 → R:aGG   GP
  7730                 SNP    G                A             100          100           E:GAG @ 564 → E:GAa   GP
  7775                 SNP    A                G             100          100           L:CTA @ 579 → L:CTg   GP
  7778                 SNP    C                A             100          100           R:CGC @ 580 → R:CGa   GP
  10252                SNP    A                T             1            4                                   
  10253                SNP    A                G             1            0                                   
  12694                SNP    T                A             100          100           I:ATT @ 371 → I:ATa   L
  12886                SNP    A                C             2            0             L:CTA @ 435 → L:CTc   L
  12952                SNP    A                G             100          100           L:CTA @ 457 → L:CTg   L
  13267                SNP    C                T             100          100           T:ACC @ 562 → T:ACt   L
  13607                SNP    G                A             1            4             V:GTC @ 676 → I:aTC   L
  13624                SNP    T                G             1            0             N:AAT @ 681 → K:AAg   L
  13630                SNP    A                G             100          100           P:CCA @ 683 → P:CCg   L

\*EBOV, Ebola virus; GP; glycoprotein, ; L, RNA-dependent RNA polymerase; LIB, Liberia; NP; nucleoprotein; SNP, single-nucleotide polymorphism; WA, Western Africa.

Several of the 27 previously identified changes (green in [Figure 2](#F2){ref-type="fig"}) already have been demonstrated to be tolerated while maintaining efficacy ([@R24],[@R30],[@R32]--[@R34]), thus minimizing their potential effect ([@R6]). Six of these 33 SNPs (EBOV-LIB \<100%; orange in [Figure 2](#F2){ref-type="fig"}) appeared during the surveillance period of this study (September 23, 2014--February 14, 2015) in samples obtained in Liberia ([@R12]). None of these changes have been previously associated with EBOV resistance to any therapeutic drug. Five of the new changes might affect 1 of the components of the ZMapp antibody cocktail (mAb 13C6). However, the conformational target site for this antibody (positions 1--295, soluble glycoprotein) is broader in length and more poorly defined than the other sequence-based countermeasure targets considered in our risk assessment. The sixth mutation might affect the binding site of the siRNA viral protein (VP) 35 target (for that particular sample, the mutation appears in an area of low sequencing coverage depth). Thus, when these new changes are combined with the changes observed previously (yellow in [Figure 2](#F2){ref-type="fig"}), we can conclude that retesting several therapeutic drugs against isolates currently circulating might be necessary to determine whether any of these mutations impact their efficacy. In particular, it is important to reevaluate drugs that include mAb 13C6 (part of the ZMapp, ZMAb, and MB-003 antibody cocktails), mAb 13F6 (part of MB-003), mAb 1H3 (part of ZMAb), and the siRNA VP35 targets ([Table 3](#T3){ref-type="table"}, [Figure 2](#F2){ref-type="fig"}) ([@R6]).

Discussion
==========

Our study details the establishment of a genomic sequencing and analysis center within Liberia for real-time monitoring of viral evolution. The initial sequences generated at this facility have provided a first glimpse into EBOV/Mak evolution from the end of 2014 to the beginning of 2015. Although genetically diverse, the viruses circulating in Liberia during this period are consistent with a single introduction event followed by diversification within Liberia. The cluster 2 haplotype from which all the sampled Liberia sequences radiate is thought to have been circulating in Guinea and Sierra Leone during late May 2014 ([@R12]). Moreover, it was the second most common sequence detected in Sierra Leone during late May through mid-June ([@R12]). Introduction of this haplotype from either of these neighboring countries could have resulted in the sampled diversity; however, we cannot rule out the possibility of multiple introductions. Additional spatial and temporal sampling within Liberia, Guinea, and Sierra Leone will help to differentiate these 2 scenarios.

The 25 Liberia EBOV/Mak genomes included 23 nonsynonymous mutations and 1 nonsense mutation that have not previously been seen in Western Africa (although some of these mutations have been observed in EBOV isolates from previous EVD outbreaks). A nonsense mutation, which is present within 2 of the 25 sequences, is predicted to result in premature truncation (6 aa) of VP30. VP30 is an essential protein for viral transcription; it is needed for the RNA-dependent RNA polymerase (L) to read beyond a *cis*-RNA element in the nucleoprotein mRNA 5′ untranslated region ([@R35]) and is required to reinitiate transcription at gene junctions ([@R36]). Moreover, VP30 phosphorylation modulates the composition and function of the RNA synthesis machinery ([@R37]). To our knowledge, no functional domains have been described in the truncated region. Further characterization is needed to determine whether this or any of the other detected mutations impacted the relative fitness of the affected EBOV isolates. Within Liberia, geography showed little correlation with phylogeny; most EBOV lineages within Liberia appear to be geographically widespread within the sampled regions.

Previous analysis of EBOV/Mak genomes from Sierra Leone and Guinea suggests that the evolutionary rate within the current EVD outbreak might be higher than the rate between outbreaks ([@R12]). After incorporation of sequences from Liberia, which were collected later in the outbreak, our estimates of substitution rate fell between the previous estimates for EBOV/Mak only and for all EBOV ([@R12],[@R38]). As more sequence data become available, it will be interesting to see whether a significant change in the evolutionary rate can be detected within the current EVD outbreak.

Our ability to quantify international EBOV exchange is limited because few isolates from other countries were available during the sampled timeframe. However, shared ancestry between isolates from Mali and 3 isolates from Liberia suggests at least 1 transmission event across national borders ([@R3]). All EVD cases in Mali have been attributed to movement of infected persons into Mali from Guinea ([@R39]). With the current dataset, it is impossible to say whether the shared Liberia/Mali lineage originated in Liberia and was then transported to Mali through Guinea or whether the lineage emerged in Guinea and later moved independently to Liberia and Mali. Active EBOV outbreaks were occurring in both Liberia and Guinea during the period estimated for the emergence of this shared lineage (July--September 2014).

The genomic changes observed for EBOV/Mak during its circulation in Liberia append 5 additional mutations to the list of changes that might affect the binding of the 13C6 mAb, a component of ZMapp. All of these changes, however, were present at relatively low frequency ([\<]{.ul}12%) in our current sample, and none of the sampled lineages have accumulated \>1 change per therapeutic drug type. We observed no significant changes (i.e., likely to affect efficacy) in the binding sites for the 2 diagnostic assays known to be used in Liberia. Overall, no dramatic changes were observed in the samples evaluated; the risk assessment for the impact of genomic drift during the outbreak should remain low. As previously stated ([@R6]), our analysis is not without caveats. Our current analysis covers only the late period of the outbreak in Liberia; no analysis has yet been published with data for similar time points from Guinea or Sierra Leone. In addition, to complete our assessment of the evolution of EBOV in Liberia, an earlier period of time from the introduction of the virus in March 2014 to early September 2014 needs to be investigated.

Our findings offer a concise evaluation of the potential impact of the evolution of EBOV/Mak based on genome reconstruction of 25 isolates from Liberia obtained during September 2014--February 2015. This work would not have been possible without the establishment of a genomic surveillance capability in Liberia, which emphasizes the need for global sequencing capabilities to be part of the first response during future virus outbreaks.
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